Celgene Corp (CELG) 107.49 $CELG
Juno Therapeutics Finishes Q3 in Good Shape Where It Matters Most
Keith Speights, The Motley Fool - Motley Fool - Sat Nov 14, 11:19AM CST
Image Source: Juno Therapeutics Can a company report its quarterly financial results and most of the numbers not be all that important? Absolutely -- if that company is a development-stage biotech. Juno Therapeutics announced its third-quarter...
JUNO: 50.00 (+0.11), CELG: 107.49 (-1.53)
Celgene Falls 2.84% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 12, 4:59PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $108.98 to a high of $112.00. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $112.15 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 107.49 (-1.53)
Celgene (CELG) Stock Showing Signs of a Downtrend
at The Street - Thu Nov 12, 3:00PM CST
Our indicators are pointing to lower prices for Celgene (CELG).
CELG: 107.49 (-1.53)
Celgene Showing Signs of a Downtrend (Plus: BBY, ANTM, NWL)
at The Street - Thu Nov 12, 2:30PM CST
Our indicators are pointing to lower prices for CELG.
ANTM: 132.55 (-0.88), NWL: 42.68 (-1.54), BBY: 32.04 (-1.95), CELG: 107.49 (-1.53)
4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 12, 5:58AM CST
Image source: U.S. Food and Drug Administration. The wait is over. Last Thursday, before the opening bell, biotech blue-chip stock Celgene reported its third-quarter earnings results. Expectations were high for the fast-growing drugmaker, but...
MRK: 53.03 (unch), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), CELG: 107.49 (-1.53)
Juno Therapeutics Posts Wider-than-Expected Loss in Q3
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 8:52AM CST
Investor focus will remain on Juno's (JUNO) cash burn and its pipeline progress.
ACHN: 9.97 (+0.12), JUNO: 50.00 (+0.11), BXLT: 33.79 (+0.54), CELG: 107.49 (-1.53)
3 Stocks We're Never Selling
Todd Campbell, Tyler Crowe, and Andrés Cardenal, The Motley Fool - Motley Fool - Tue Nov 10, 2:39PM CST
It's been proven time and time again that long-term investing outperforms short-term trading, and with that in mind, we asked some of our top Motley Fool contributors to highlight stocks they have no intention of selling from their portfolios. ...
WM: 52.16 (-0.61), CELG: 107.49 (-1.53)
3 Midsize Drug Stocks Moving On Q3 Reports
at Investor's Business Daily - Tue Nov 10, 12:34PM CST
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals...
JNJ: 99.88 (-0.39), HALO: 15.41 (+0.10), JAZZ: 134.77 (+0.76), HZNP: 17.99 (+0.38), DEPO: 18.69 (-0.99), CELG: 107.49 (-1.53)
Epizyme's Q3 Loss Wider-Than-Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 8:34AM CST
Epizyme (EPZM) reported a wider-than-expected loss in the third quarter of 2015.
ICPT: 181.01 (-0.90), EPZM: 15.75 (+0.23), BXLT: 33.79 (+0.54), CELG: 107.49 (-1.53)
'Mad Money' Lightning Round: Buy Delta Air Lines and Nordic American Tanker
at The Street - Tue Nov 10, 5:00AM CST
Cramer likes certain airlines but doesn't want to be in apparel.
PRTY: 13.13 (-1.75), DAL: 48.99 (-0.99), KMB: 117.32 (-0.37), LUV: 45.89 (-0.80), CELG: 107.49 (-1.53), LGF: 37.84 (-3.23), CHK: 6.10 (-0.22), TOO: 13.00 (-0.07), NAT: 14.87 (-0.19), AAL: 43.45 (-0.45), CRI: 85.03 (-1.34), EROS: 7.08 (-1.82), SWHC: 17.14 (-0.47)
Jim Cramer's 'Mad Money' Recap: Opportunities as Rates Rise
at The Street - Mon Nov 09, 7:10PM CST
Cramer says investors shouldn't panic when rates rise.
VRX: 75.41 (+1.64), CYBR: 38.78 (-1.48), PRTY: 13.13 (-1.75), DAL: 48.99 (-0.99), KMB: 117.32 (-0.37), PCL: 46.19 (-0.34), CELG: 107.49 (-1.53), LUV: 45.89 (-0.80), LGF: 37.84 (-3.23), CHK: 6.10 (-0.22), TOO: 13.00 (-0.07), HZNP: 17.99 (+0.38), NAT: 14.87 (-0.19), WY: 29.25 (-0.14), APA: 48.97 (+0.07), COST: 153.67 (-2.33), AAL: 43.45 (-0.45), HAWK: 44.53 (-0.12), CRI: 85.03 (-1.34), GPS: 25.23 (-1.29), EROS: 7.08 (-1.82), SWHC: 17.14 (-0.47)
After Yesterday's Decline of 2.28%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Mon Nov 09, 4:17PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $113.26 to a high of $116.00. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $113.99 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 107.49 (-1.53)
3 Biotech Stocks That Are Rocketing Higher
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 09, 2:41PM CST
Source: Flickr user Steve Jurvetson The biotech industry may have lost a bit of its luster with investors lately, but some biotech stocks are still generating eye-popping returns that suggest people remain willing to bet on game-changing medicine....
PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), FOLD: 10.48 (+0.49), CELG: 107.49 (-1.53), XLRN: 35.47 (-0.09)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Celgene (CELG) Stock Will Eventually Break Out of Sideways Trend
at The Street - Mon Nov 09, 11:38AM CST
Celgene (CELG) shares have been largely stuck in a $20 trading range over the past 12 months.
CELG: 107.49 (-1.53)
Celgene Will Break Out of Sideways Trend, Eventually
at The Street - Mon Nov 09, 11:08AM CST
Shares are largely stuck in a $20 trading range the past 12 months.
CELG: 107.49 (-1.53)
Juno Therapeutics Finishes Q3 in Good Shape Where It Matters Most
Keith Speights, The Motley Fool - Motley Fool - Sat Nov 14, 11:19AM CST
Image Source: Juno Therapeutics Can a company report its quarterly financial results and most of the numbers not be all that important? Absolutely -- if that company is a development-stage biotech. Juno Therapeutics announced its third-quarter...
JUNO: 50.00 (+0.11), CELG: 107.49 (-1.53)
Celgene Falls 2.84% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 12, 4:59PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $108.98 to a high of $112.00. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $112.15 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 107.49 (-1.53)
Celgene (CELG) Stock Showing Signs of a Downtrend
at The Street - Thu Nov 12, 3:00PM CST
Our indicators are pointing to lower prices for Celgene (CELG).
CELG: 107.49 (-1.53)
Celgene Showing Signs of a Downtrend (Plus: BBY, ANTM, NWL)
at The Street - Thu Nov 12, 2:30PM CST
Our indicators are pointing to lower prices for CELG.
ANTM: 132.55 (-0.88), NWL: 42.68 (-1.54), BBY: 32.04 (-1.95), CELG: 107.49 (-1.53)
4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 12, 5:58AM CST
Image source: U.S. Food and Drug Administration. The wait is over. Last Thursday, before the opening bell, biotech blue-chip stock Celgene reported its third-quarter earnings results. Expectations were high for the fast-growing drugmaker, but...
MRK: 53.03 (unch), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), CELG: 107.49 (-1.53)
Juno Therapeutics Posts Wider-than-Expected Loss in Q3
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 8:52AM CST
Investor focus will remain on Juno's (JUNO) cash burn and its pipeline progress.
ACHN: 9.97 (+0.12), JUNO: 50.00 (+0.11), BXLT: 33.79 (+0.54), CELG: 107.49 (-1.53)
3 Stocks We're Never Selling
Todd Campbell, Tyler Crowe, and Andrés Cardenal, The Motley Fool - Motley Fool - Tue Nov 10, 2:39PM CST
It's been proven time and time again that long-term investing outperforms short-term trading, and with that in mind, we asked some of our top Motley Fool contributors to highlight stocks they have no intention of selling from their portfolios. ...
WM: 52.16 (-0.61), CELG: 107.49 (-1.53)
3 Midsize Drug Stocks Moving On Q3 Reports
at Investor's Business Daily - Tue Nov 10, 12:34PM CST
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals...
JNJ: 99.88 (-0.39), HALO: 15.41 (+0.10), JAZZ: 134.77 (+0.76), HZNP: 17.99 (+0.38), DEPO: 18.69 (-0.99), CELG: 107.49 (-1.53)
Epizyme's Q3 Loss Wider-Than-Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 8:34AM CST
Epizyme (EPZM) reported a wider-than-expected loss in the third quarter of 2015.
ICPT: 181.01 (-0.90), EPZM: 15.75 (+0.23), BXLT: 33.79 (+0.54), CELG: 107.49 (-1.53)
'Mad Money' Lightning Round: Buy Delta Air Lines and Nordic American Tanker
at The Street - Tue Nov 10, 5:00AM CST
Cramer likes certain airlines but doesn't want to be in apparel.
PRTY: 13.13 (-1.75), DAL: 48.99 (-0.99), KMB: 117.32 (-0.37), LUV: 45.89 (-0.80), CELG: 107.49 (-1.53), LGF: 37.84 (-3.23), CHK: 6.10 (-0.22), TOO: 13.00 (-0.07), NAT: 14.87 (-0.19), AAL: 43.45 (-0.45), CRI: 85.03 (-1.34), EROS: 7.08 (-1.82), SWHC: 17.14 (-0.47)
Jim Cramer's 'Mad Money' Recap: Opportunities as Rates Rise
at The Street - Mon Nov 09, 7:10PM CST
Cramer says investors shouldn't panic when rates rise.
VRX: 75.41 (+1.64), CYBR: 38.78 (-1.48), PRTY: 13.13 (-1.75), DAL: 48.99 (-0.99), KMB: 117.32 (-0.37), PCL: 46.19 (-0.34), CELG: 107.49 (-1.53), LUV: 45.89 (-0.80), LGF: 37.84 (-3.23), CHK: 6.10 (-0.22), TOO: 13.00 (-0.07), HZNP: 17.99 (+0.38), NAT: 14.87 (-0.19), WY: 29.25 (-0.14), APA: 48.97 (+0.07), COST: 153.67 (-2.33), AAL: 43.45 (-0.45), HAWK: 44.53 (-0.12), CRI: 85.03 (-1.34), GPS: 25.23 (-1.29), EROS: 7.08 (-1.82), SWHC: 17.14 (-0.47)
After Yesterday's Decline of 2.28%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Mon Nov 09, 4:17PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $113.26 to a high of $116.00. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $113.99 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 107.49 (-1.53)
3 Biotech Stocks That Are Rocketing Higher
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 09, 2:41PM CST
Source: Flickr user Steve Jurvetson The biotech industry may have lost a bit of its luster with investors lately, but some biotech stocks are still generating eye-popping returns that suggest people remain willing to bet on game-changing medicine....
PFE: 33.27 (-0.12), CLLS: 35.83 (-0.53), FOLD: 10.48 (+0.49), CELG: 107.49 (-1.53), XLRN: 35.47 (-0.09)
What Does 2016 Hold for This Closely-Watched Biotech ETF?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 09, 12:49PM CST
The iShares Nasdaq Biotechnology ETF is a quick and easy way to gain exposure to a wide variety of biotech and pharmaceutical equities listed on the NASDAQ. As an added bonus, this ETF is designed to limit the risk of major downward price...
BIIB: 284.84 (-6.49), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), IBB: 323.64 (+3.53), REGN: 548.90 (-3.63), CELG: 107.49 (-1.53)
Celgene (CELG) Stock Will Eventually Break Out of Sideways Trend
at The Street - Mon Nov 09, 11:38AM CST
Celgene (CELG) shares have been largely stuck in a $20 trading range over the past 12 months.
CELG: 107.49 (-1.53)
Celgene Will Break Out of Sideways Trend, Eventually
at The Street - Mon Nov 09, 11:08AM CST
Shares are largely stuck in a $20 trading range the past 12 months.
CELG: 107.49 (-1.53)
